About AIRDOC-B Company

Eagle Eye Airdoc was founded in September 2015 and is headquartered in Beijing. By the end of January 2020, the company had set up subsidiaries and R&D centers in Beijing, Shanghai, Guangzhou and Hong Kong. Eagle Eye Airdoc is a global leader and pioneer in the field of retinal imaging artificial intelligence. The company's early detection, auxiliary diagnosis and health risk assessment solutions based on retinal image artificial intelligence recognition have improved traditional early detection and diagnosis methods of chronic diseases through retinal imaging, multi-modal data analysis, and artificial intelligence deep learning algorithms to achieve non-invasive, accurate, fast, cost-effective and large-scale diagnosis of chronic diseases and related health risk assessments in medical institutions and large health scenarios. In August 2020, the Hawkeye Airdoc diabetic retinopathy under-eye imaging diagnostic software was approved and marketed by the National Drug Administration. It was the first such product to obtain a Class III medical device certificate from the National Drug Administration, and as a result, it began to be used in domestic hospitals to assist and mitigate doctors' medical diagnosis work. In order to solve unmet medical and health needs, the company has developed a rich product pipeline related to artificial intelligence retinal imaging, which has been widely used in community clinics, physical examination centers, insurance companies, optometry centers, pharmacies, etc., to provide users with assisted disease diagnosis and health risk assessment.